{"id":69005,"date":"2026-03-13T11:51:26","date_gmt":"2026-03-13T11:51:26","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=69005"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"cjc-1295-without-dac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/cjc-1295-without-dac\/","title":{"rendered":"CJC-1295 zonder DAC"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is CJC-1295 without DAC?<\/h3>\n

CJC-1295 zonder DAC<\/strong> (also called Mod GRF 1-29<\/strong>) is a synthetic modified GHRH (1-29) analog with a short ~30-minute plasma half-life. Unlike the DAC version, it lacks the albumin-binding tether, producing a pulsatile<\/strong> rather than sustained GH signal. This kinetic profile makes it the preferred research tool when pulse-timing matters. Supplied in 2\u00a0mg to 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n863288-34-0 (parent) \u00b7 446262-90-4 (Mod-GRF 1\u201329 form widely cited)<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC152<\/sub>H252<\/sub>N44<\/sub>O42<\/sub><\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n3367.92 Da<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nD-Ala-Tyr-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2<\/sub> (Mod-GRF 1\u201329, no DAC linker)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (of zoals geleverd)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatisch water (aanbevolen) of steriel water voor kortere gebruiksperioden<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is CJC-1295 without DAC?<\/h2>\n

CJC-1295 zonder DAC<\/strong> (commonly called Mod GRF 1-29<\/strong> or simply tetrasubstituted GRF 1-29<\/strong>) is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone. It shares the same core peptide sequence as CJC-1295 met DAC<\/a> \u2014 four amino-acid substitutions on the native GHRH (1-29) sequence provide resistance to DPP-IV cleavage \u2014 but lacks the albumin-binding DAC modification<\/strong> that extends half-life in the “with DAC” version.<\/p>\n

The practical consequence of no DAC: plasma half-life remains in the minutes-to-hours range (~30 minutes) rather than days. Research protocols therefore use multiple daily injections (typically 2\u20133x) to maintain GHRH signal rather than the weekly dosing of the DAC version. This mimics the short, pulsatile profile of endogenous GHRH and is the preferred research tool when pulse-timing matters \u2014 particularly in protocols studying physiological GH pulsatility alongside ghrelin-receptor agonists such as ipamorelin<\/a>.<\/p>\n

Molecular weight approximately 3,367\u00a0Da. Supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. CJC-1295 without DAC is uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary diagnosis or therapy. For mechanism, research context, and stacking protocols, see our Ipamorelin & CJC-1295 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Pulsatile GHRH Signaling<\/h2>\n

Mod GRF 1-29 acts through the same pituitary GHRH receptor pathway as native GHRH, but with a kinetic profile that distinguishes it from both native GHRH and the DAC version:<\/p>\n